FIELD: medicine; pharmaceutics.
SUBSTANCE: present invention relates to a novel compound of chemical formula I, or a pharmaceutically acceptable salt thereof, where 
is 
; each of R4 and R5 is independently C1-C4 alkyl; Z5 is N-R6 or CH2; R6 is C1-C4 alkyl, -C(=O)-(C1-C4 alkyl), -C (=O)-O-(C1-C4 alkyl) or 4–6 membered heterocycloalkyl having one O; L1 is -(C1-C2 alkylene)-; 
is C6-C12 aryl, 5–9 membered heteroaryl having at least one N, or 
; each of R2 and R3 independently represents H, halogen, C6-C12 aryl, 5- or 6-member heteroaryl, having N or O, 5- or 6-member heterocycloalkyl, having N, 5- or 6-member heterocycloalkenyl having N, -C(=O)-O-(C1-C4 alkyl), -C(=O)-(C1-C4 alkyl), -NH-C(=O)-(C1-C4 alkyl), -NO2 or -NH2, at least one H of the above R2 and R3 can in each case be independently substituted with halogen or C1-C4 alkyl; and n, and m in each case is independently equal to 1 or 2. Invention also relates to a pharmaceutical composition containing a compound of chemical formula I, to a method for preventing or treating diseases mediated by histone deacetylase (HDAC), and to the use of a compound of chemical formula I for preventing or treating diseases mediated by HDAC.
EFFECT: enabling development of a selective inhibitor of HDAC6, which has a zinc-binding group, with improved bioavailability, which does not cause side effects, for treating cancer, inflammatory, autoimmune and neurological diseases, neurodegenerative disorders.
10 cl, 2 tbl, 38 ex
